FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1013875744> ?p ?o ?g. }

• W1013875744 endingPage "e76" @default.
• W1013875744 startingPage "e76" @default.
• W1013875744 abstract "Su and Rau1Su YL Rau KM Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.J Thorac Oncol. 2015; 10: e21-e22Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar have recently reported a case of non–small-cell lung cancer (NSCLC) of great interest. The patient, with anaplastic lymphoma kinase (ALK)-positive adenocarcinoma of the lung with brain metastases, was initially treated with whole-brain irradiation and then treated with chemotherapy consisting of pemetrexed and cisplatin; however, her brain metastases increased in size accompanied by muscle weakness and myoclonic jerks after two cycles of chemotherapy. The authors then added bevacizumab to the same chemotherapy and the brain metastases markedly shrank. To date, it has been prospectively demonstrated that bevacizumab is safe and effective in NSCLC patients with brain metastases as long as these metastases are pretreated2Socinski MA Langer CJ Huang JE et al.Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.J Clin Oncol. 2009; 27: 5255-5261Crossref PubMed Scopus (223) Google Scholar or asymptomatic.3Besse B Le Moulec S Mazières J et al.Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study.Clin Cancer Res. 2015; 21: 1896-1903Crossref PubMed Scopus (170) Google Scholar Moreover, a case series has shown that bevacizumab is also safe and effective for NSCLC patients with symptomatic, heavily pretreated brain metastases.4De Braganca KC Janjigian YY Azzoli CG et al.Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.J Neurooncol. 2010; 100: 443-447Crossref PubMed Scopus (90) Google Scholar We also experienced a case of lung adenocarcinoma in which the brain metastases were refractory to whole-brain irradiation but dramatically responded to combination chemotherapy of bevacizumab, paclitaxel, and carboplatin (Fig. 1). These findings suggest that bevacizumab may merit further investigation in NSCLC patients with symptomatic, heavily pretreated, and/or radioresistant brain metastases. In addition, a recent retrospective study demonstrated that brain metastases are considerably common at the time of diagnosis and also at the time of disease progression in epidermal growth factor receptor (EGFR)-positive or ALK-positive NSCLC treated with tyrosine kinase inhibitors (TKIs).5Rangachari D Yamaguchi N VanderLaan PA et al.Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.Lung Cancer. 2015; 88: 108-111Abstract Full Text Full Text PDF PubMed Scopus (283) Google Scholar Considering that bevacizumab may have some booster effect for brain metastases and that brain metastases have a negative impact on survival in EGFR-positive NSCLC treated with EGFR-TKI as well,6Noronha V Joshi A Gokarn A et al.The importance of brain metastasis in EGFR mutation positive NSCLC patients.Chemother Res Pract. 2014; 2014: 856156PubMed Google Scholar prospective evaluation of bevacizumab in combination with TKI in EGFR-positive or ALK-positive NSCLC patients with brain metastases would be particularly valuable." @default.
• W1013875744 created "2016-06-24" @default.
• W1013875744 creator A5042756499 @default.
• W1013875744 creator A5090487149 @default.
• W1013875744 date "2015-08-01" @default.
• W1013875744 modified "2023-10-17" @default.
• W1013875744 title "Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non–Small-Cell Lung Cancer with Brain Metastases" @default.
• W1013875744 cites W2041835001 @default.
• W1013875744 cites W2060572930 @default.
• W1013875744 cites W2069510682 @default.
• W1013875744 cites W2078803344 @default.
• W1013875744 cites W2136371443 @default.
• W1013875744 cites W2159711942 @default.
• W1013875744 doi "https://doi.org/10.1097/jto.0000000000000568" @default.
• W1013875744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26200284" @default.
• W1013875744 hasPublicationYear "2015" @default.
• W1013875744 type Work @default.
• W1013875744 sameAs 1013875744 @default.
• W1013875744 citedByCount "0" @default.
• W1013875744 crossrefType "journal-article" @default.
• W1013875744 hasAuthorship W1013875744A5042756499 @default.
• W1013875744 hasAuthorship W1013875744A5090487149 @default.
• W1013875744 hasBestOaLocation W10138757441 @default.
• W1013875744 hasConcept C117643217 @default.
• W1013875744 hasConcept C121608353 @default.
• W1013875744 hasConcept C126322002 @default.
• W1013875744 hasConcept C143998085 @default.
• W1013875744 hasConcept C2776232967 @default.
• W1013875744 hasConcept C2776256026 @default.
• W1013875744 hasConcept C2776694085 @default.
• W1013875744 hasConcept C2777240266 @default.
• W1013875744 hasConcept C2777802072 @default.
• W1013875744 hasConcept C2778164965 @default.
• W1013875744 hasConcept C2778239845 @default.
• W1013875744 hasConcept C2779013556 @default.
• W1013875744 hasConcept C2781182431 @default.
• W1013875744 hasConcept C71924100 @default.
• W1013875744 hasConceptScore W1013875744C117643217 @default.
• W1013875744 hasConceptScore W1013875744C121608353 @default.
• W1013875744 hasConceptScore W1013875744C126322002 @default.
• W1013875744 hasConceptScore W1013875744C143998085 @default.
• W1013875744 hasConceptScore W1013875744C2776232967 @default.
• W1013875744 hasConceptScore W1013875744C2776256026 @default.
• W1013875744 hasConceptScore W1013875744C2776694085 @default.
• W1013875744 hasConceptScore W1013875744C2777240266 @default.
• W1013875744 hasConceptScore W1013875744C2777802072 @default.
• W1013875744 hasConceptScore W1013875744C2778164965 @default.
• W1013875744 hasConceptScore W1013875744C2778239845 @default.
• W1013875744 hasConceptScore W1013875744C2779013556 @default.
• W1013875744 hasConceptScore W1013875744C2781182431 @default.
• W1013875744 hasConceptScore W1013875744C71924100 @default.
• W1013875744 hasIssue "8" @default.
• W1013875744 hasLocation W10138757441 @default.
• W1013875744 hasLocation W10138757442 @default.
• W1013875744 hasOpenAccess W1013875744 @default.
• W1013875744 hasPrimaryLocation W10138757441 @default.
• W1013875744 hasRelatedWork W1602357875 @default.
• W1013875744 hasRelatedWork W2358450743 @default.
• W1013875744 hasRelatedWork W2475550520 @default.
• W1013875744 hasRelatedWork W2516942920 @default.
• W1013875744 hasRelatedWork W2743740828 @default.
• W1013875744 hasRelatedWork W2768988395 @default.
• W1013875744 hasRelatedWork W2891900934 @default.
• W1013875744 hasRelatedWork W3029430426 @default.
• W1013875744 hasRelatedWork W4256013750 @default.
• W1013875744 hasRelatedWork W49755809 @default.
• W1013875744 hasVolume "10" @default.
• W1013875744 isParatext "false" @default.
• W1013875744 isRetracted "false" @default.
• W1013875744 magId "1013875744" @default.
• W1013875744 workType "article" @default.